Causes
Before the discovery of the bacterium Helicobacter (H.) pylori, the stomach was believed to be a sterile environment. Now, H. pylori is known to be a major cause of peptic ulcers. The bacteria appears to trigger ulcers in the following way:
-
H. pylori's corkscrew shape enables it to penetrate the mucous layer of the stomach or duodenum so that it can attach itself to the lining.
- It survives its highly acidic environment by producing urease, an enzyme that generates ammonia and neutralizes the acid.
-
H. pylori then produces a number of toxins and factors that in certain individuals cause inflammation and damage to the lining, leading to ulcers.
- It also alters certain immune factors that allow it to evade detection and cause persistent inflammation for a person's lifetime--even without invading the mucous membrane.
Even if ulcers do not develop, the bacterium is now considered to be a major cause of active chronic inflammation in the stomach (gastritis) and in the upper part of the small intestine (duodenitis).
It is also strongly linked to stomach (gastric) cancer and possibly other non-intestinal problems.
Factors That Trigger Ulcers in H. pylori Carriers. It should be noted that H. pylori is found in about 25% of people who do not have peptic ulcers. The magnitude of H. pylori infection, particularly in older people, may not always predict the presence or absence of peptic ulcers. Other variables, then, need to be present to actually trigger ulcers. They may include the following:
- Genetic Factors. Some people harbor genetic strains of H. pylori that may make the bacteria more dangerous and increase the risk for ulcers in infected individuals. The most intensively investigated genetic factor is cytotoxin-associated gene A (CagA), which has been associated with both gastric and duodenal ulcers as will as with stomach cancer. Other genetic types that may also increase bacterial severity are called vacuolating cytotoxin (vacA) and antigen-binding adhesin (BabA) genotypes. Some of these genetic factors may be more or less important for development of ulcers depending on ethnicity.
- Immune Abnormalities. Some experts suggest that certain individuals have abnormalities in the immune response in the intestine that allow the bacteria to become injurious to the lining.
- Lifestyle Factors. Although lifestyle factors (e.g., chronic stress, coffee-drinking, smoking) were long believed to be the primary cause of ulcers, it is now thought they only increase susceptibility to them in some H. pylori carriers.
When H. pylori was first identified as the major cause of peptic ulcers, it was found in 90% of people with duodenal ulcers and in about 80% of people with gastric ulcers. As more people are being tested and treated for the bacteria, however, the rate of H. pylori associated ulcers has declined. For example, a 2001 study suggested that about half of ulcers are not caused by H. pylori. Instead, they tend to be due to regular use of nonsteroidal anti-inflammatory drugs (NSAIDs), which include aspirin and other common pain relievers. Genetic factors, or, rarely, Crohn's disease or Zollinger-Ellison syndrome also cause ulcers.
Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
Long-term use of nonsteroidal anti-inflammatory drugs (NSAIDs) is the second most common cause of ulcers and the rate of NSAID-caused ulcers is increasing. About 20 million people take prescription NSAIDs regularly, and over 25 billion tablets of over-the-counter brands are sold each year in America. The most common NSAIDs are aspirin, ibuprofen (Advil), and naproxen (Aleve, Naprosyn), although many others are available.
Their damaging effects appears to rest primarily on actions that block an enzyme called cyclooxygenase (COX), which is involved in the production of prostaglandins. The COX enzyme has two forms:
- COX-2 causes intestinal contractions and inflammation. When NSAIDs block this enzyme, they help reduce pain and inflammation. This is their primary benefit.
- COX-1 also protects the stomach by its release of prostaglandins that protect the mucous layer, maintain normal bicarbonate levels, and keep blood flowing in the intestinal tract. When NSAIDs block COX-2, they expose the mucous lining to attack.
Standard NSAIDs block both COX-1 and COX-2. Even if an NSAID is injected intravenously, the drug will still inhibit prostaglandins in the stomach and duodenum. NSAIDs are mild acids and can cause some injury by direct exposure to the lining of the stomach. Their primary damaging effects, however, are from their actions against COX-1. Studies suggest the following risks:
- An analysis of controlled trials reported that about 1% of patients taking aspirin over a 28 month period will experience gastrointestinal bleeding. A significant risk existed even at low doses or with the use of modified-release formulations.
- Of further concern was a 1998 study indicating that taking NSAIDs for only six months posed a risk for symptomatic ulcers that was greater than 1%.
The risk for bleeding is continuous for as long as a patient is on these drugs and may even persist for about a year after taking them. Taking short courses of NSAIDs for temporary pain relief should not cause major problems because the stomach has time to recover and repair any damage that has occurred.
Specific NSAIDs pose greater or lesser risks for ulcers and bleeding. No NSAIDs, however, even over-the-counter brands, should be used long-term except under a physician's direction.
Ulcer Risk by Specific NSAIDs
|
|
Lowest Risk
|
Medium Risk
|
Highest Risk
|
|
Nabumetone (Relafen)
Etodolac (Lodine)
Salsalate
Sulindac (Clinoril)
|
Aspirin. Even low-dose aspirin (81 mg) used to protect the heart may pose some risk (although lower than standard doses).
Ibuprofen (Motrin, Advil, Nuprin, Rufen)
Naproxen (Aleve, Naprosyn, Naprelan, Anaprox)
Diclofenac (Voltaren) Tolmetin (Tolectin)
NOTE: Drugs within the medium risk group vary in risk. For example, studies show that use of naproxen is twice as likely as ibuprofen to be associated with hospitalization from GI bleeding.
|
Flurbiprofen (Ansaid) Piroxicam (Feldene) Fenoprofen Indomethacin (Indocin) Meclofenamate (Meclomen)
Ketoprofen (Actron, Orudis KT) NOTE: Ketoprofen is often considered a medium-risk drug, but one study reported that taking the drug even one week at low doses causes significant GI injury.
|
Other Causes
The least common major cause of peptic ulcer disease is the Zollinger-Ellison syndrome (ZES).
Rarely, certain conditions may cause ulceration in the stomach or intestine, including:
- Radiation treatments.
- Bacterial or viral infections.
- Alcohol abuse.
- Physical injury.
- Burns.
Zollinger-Ellison Syndrome (ZES)
What is ZES?
The least common major cause of peptic ulcer disease is the Zollinger-Ellison syndrome (ZES). In this condition, gastrinomas (tumors in the pancreas and the duodenum) produce excessive amounts of gastrin, a hormone that stimulates gastric acid formation. These tumors are usually malignant, so proper and prompt management of the disease is essential.
|
|
| A major cause of peptic ulcer, although far less common than H.pylori or NSAIDS, is Zollinger-Ellison syndrome. A large amount of excess acid is produced in response to the overproduction of the hormone gastrin, which in turn is caused by tumors on the pancreas or duodenum. These tumors are usually malignant, must be removed and acid production suppressed to relieve the recurrence of the ulcers. |
|
Who Gets ZES?
The incidence of ZES in the United States is estimated at one case per million people per year, and at 0. 1% to 1% among patients with peptic ulcers. The mean age at onset is 45 to 50 years, and men are affected more often than women.
How Is ZES Diagnosed?
ZES should be suspected in patients with ulcers who are not infected with H. pylori and have no history of NSAID use. Diarrhea may precede ulcer symptoms. Ulcers occurring in the second, third, or fourth portions of the duodenum or the jejunum (the middle section of the small intestine) are signs of the syndrome. Gastroesophageal reflux disease (backflow of the stomachs contents into the esophagus) is more prevalent and often more severe in patients with ZES, and can be complicated by ulcerations and strictures of the esophagus.
How Is ZES Treated?
Peptic ulcers associated with ZES are typically persistent and difficult to treat. Treatment consists of removing the tumors and suppressing acid with intravenous proton-pump inhibitors (Protonix). Proton-pump inhibitors block acid production and are a major advance for these patients. Previously, removing the stomach was the only option.
|
|